PROTAGONIST THERAPEUTICS, INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 31.26 USD | +1.69% |
|
+6.62% | +36.33% |
Presenter SpeechMatthew Gosling (Executives)Good morning. I'm Matthew Gosling, the Executive V...
This article is reserved for subscribers
Signed up already?
Log InNot subscribed yet?
Subscribe
Protagonist Therapeutics, Inc. is a biopharmaceutical company. The Company uses its peptide-based chemical entities rusfertide and JNJ-2113 in different stages of development, all derived from its proprietary discovery technology platform. The Companyâs clinical programs fall into two categories of diseases: hematology and blood disorders, and inflammatory and immunomodulatory diseases. Its lead clinical asset, rusfertide (PTG-300), is an injectable hepcidin mimetic in development for the potential treatment of polycythemia vera (PV) and other blood disorders. The Companyâs Interleukin-23 receptor (IL-23R) antagonist compound JNJ-2113 is an orally delivered investigational drug that is designed to block biological pathways targeted by marketed injectable antibody drugs. Its PN-943 is a wholly owned investigational orally delivered gut-restricted alpha 4 beta 7 (α4β7) specific integrin antagonist for inflammatory bowel disease (IBD).
Calendar
2024-06-14
- European Hematology Association Meeting
Related indices
Trading Rating
Investor Rating
ESG Refinitiv
C
Sell
Buy
Mean consensus
BUY
Number of Analysts
6
Last Close Price
31.26
USD
Average target price
43.5
USD
Spread / Average Target
+39.16%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +36.33% | 1.83B | |
| +41.79% | 54.04B | |
| -0.56% | 41.92B | |
| +49.62% | 41.96B | |
| -7.20% | 28.35B | |
| +12.59% | 26.35B | |
| -21.51% | 19B | |
| +6.92% | 13B | |
| +24.91% | 12.19B | |
| +29.60% | 12.28B |
- Stock Market
- Equities
- PTGX Stock
- News Protagonist Therapeutics, Inc.
- Transcript : Protagonist Therapeutics, Inc. - Shareholder/Analyst Call
